Views & Analysis Nine for 2019: Opportunities for pharma In the last Nine for 2019 article, we reflected on the major challenges that are sha
Partner Content Partner Content Michel Mikhail invites Biosimilar experts to attend SMi’s 10... Michel Mikhail invites Biosimilar experts to attend SMi
News Sandoz strikes deal with EirGenix for Herceptin biosimilar Sandoz has struck a deal with Taiwan-based EirGenix to market a late-stage biosimilar of Roche’s breast cancer blockbuster Herceptin.
Events Partner Content SMi’s 10th Annual Biosimilars Conference Biosimilars Conference, London, Sept 2019
Partner Content Partner Content Save the date for SMi’s 10th Annual Biosimilars Conference 2... Save the date for SMi’s 10th Annual Biosimilars Conf
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
